Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

216
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
216
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

293
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
293
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

741
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
741
High-Level and Low-Level Awareness01:19

High-Level and Low-Level Awareness

425
Controlled processes in human consciousness represent high-alert mental states where individuals deliberately focus their attention on achieving specific goals. Controlled processes can be seen in situations like mastering new technology, where a person might become so absorbed that they ignore surrounding distractions. Such processes involve selective attention, requiring one to concentrate on particular elements of experience while disregarding others. These are governed by executive...
425
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

371
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
371
Intellectual Disability01:29

Intellectual Disability

206
Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
206

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing imatinib sampling strategies through a population approach: a crucial step to model-informed precision dosing validation for point-of-care therapeutic drug monitoring.

BMC pharmacology & toxicology·2026
Same author

Per- and Polyfluoroalkyl Substances Exposure and Ischemic Heart Disease: Emerging Evidence from the Literature.

Antioxidants (Basel, Switzerland)·2026
Same author

Overcoming the diagnostic gap in mild cognitive impairment in Parkinson's disease: a pilot study employing a machine learning-/augmented reality-based digital biomarker.

Frontiers in aging neuroscience·2026
Same author

Oxy-Inflammatory Profile of Finishers and No-Finishers in an Extreme Ultra-Endurance Trail Race: The 866 km Transpyrénéa.

International journal of molecular sciences·2026
Same author

Methodologies and methods for the development, evaluation and implementation of psychosocial interventions for dementia: protocol for a scoping review.

BMJ open·2026
Same author

Special Issue "Cellular and Molecular Progression of Cardiovascular Diseases".

International journal of molecular sciences·2026

Related Experiment Video

Updated: Oct 14, 2025

Methodology for Establishing a Community-Wide Life Laboratory for Capturing Unobtrusive and Continuous Remote Activity and Health Data
11:21

Methodology for Establishing a Community-Wide Life Laboratory for Capturing Unobtrusive and Continuous Remote Activity and Health Data

Published on: July 27, 2018

8.4K

Intercepting Dementia: Awareness and Innovation as Key Tools.

Emanuele Brai1,2, Alessandro Tonacci3, Victòria Brugada-Ramentol4

  • 1Brain Fit4Life, Fribourg, Switzerland.

Frontiers in Aging Neuroscience
|November 1, 2021
PubMed
Summary

Raising dementia awareness and implementing new screening methods are crucial for combating cognitive decline. These steps will drive research and develop effective treatments for this growing global health challenge.

Keywords:
advocacydementiainnovationpreventionstigma & awarenesstechnologies

More Related Videos

Assessment and Communication for People with Disorders of Consciousness
07:37

Assessment and Communication for People with Disorders of Consciousness

Published on: August 1, 2017

9.3K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.7K

Related Experiment Videos

Last Updated: Oct 14, 2025

Methodology for Establishing a Community-Wide Life Laboratory for Capturing Unobtrusive and Continuous Remote Activity and Health Data
11:21

Methodology for Establishing a Community-Wide Life Laboratory for Capturing Unobtrusive and Continuous Remote Activity and Health Data

Published on: July 27, 2018

8.4K
Assessment and Communication for People with Disorders of Consciousness
07:37

Assessment and Communication for People with Disorders of Consciousness

Published on: August 1, 2017

9.3K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.7K

Area of Science:

  • Neuroscience
  • Gerontology
  • Public Health

Background:

  • Dementia affects 50 million globally, projected to reach 150 million by 2050.
  • Neurodegenerative pathologies impose a significant economic burden, exceeding $1 trillion USD in 2020.
  • The aging population exacerbates the prevalence and impact of dementia-related disorders.

Purpose of the Study:

  • To highlight the critical need for increased dementia awareness and investment.
  • To advocate for the implementation of novel screening measures for early detection and intervention.
  • To explore how knowledge-based advocacy can accelerate clinical trials and therapeutic development.

Main Methods:

  • Discussion of the importance of public awareness campaigns to reduce stigma.
  • Analysis of the potential of new screening tools for cognitive decline.
  • Exploration of advocacy strategies to support research and drug development.

Main Results:

  • Increased awareness can help reduce stigma and encourage investment in dementia research.
  • Novel screening measures show promise in preventing and potentially reversing cognitive decline.
  • Knowledge-based advocacy is essential for advancing clinical trials and pharmacological interventions.

Conclusions:

  • A comprehensive understanding of dementia is vital for developing effective treatments.
  • Public awareness and early screening are key components in managing the dementia crisis.
  • Advocacy plays a crucial role in translating research into timely clinical applications.